A Phase 1 interventional study of BCD-131 and Mircera® in Reticulocyte Count, sponsored by Biocad. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-01.
Sponsored by Biocad · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
BCD-131-1 is an Open-Label Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, Safety and Immunogenicity of Single Ascending Doses of BCD-131 in Healthy Volunteers
BCD-131 is novel drug product of pegylated darbepoetin alfa.
Clinical trial BCD-131-1 will be conducted in two stages:
Stage I is an open-label, non-randomized clinical study of pharmacokinetics, pharmacodynamics, tolerability, safety and immunogenicity of BCD-131 given to healthy volunteers at ascending doses (Phase 1, a traditional "3+3" design).
Also, the PK and PD parameters of the closest analogues of BCD-131 (Mircera and Aranesp) given as subcutaneous injections at therapeutic doses will be evaluated.
Stage II aims to further evaluate pharmacokinetics, pharmacodynamics and safety of subcutaneous and intravenous injections of BCD-131 at a dose which ensures PD effects similar to those of the closest analogues (Mircera, Aranesp) given as subcutaneous injections at therapeutic doses.
Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy patients, which is proved by their medical history, physical examination and laboratory findings:
CBC results within normal limits, including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
Biological: BCD-131
Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
Biological: BCD-131
Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
Biological: BCD-131
Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
Biological: BCD-131
Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
Biological: BCD-131
Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
Biological: BCD-131
Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
Biological: BCD-131
Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
Biological: Mircera®
Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
Biological: Aranesp®
Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
Biological: BCD-131
Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
Biological: BCD-131
AUC (0-1176 Hours)
Area under curve (AUC) "concentration - time" from 0 hours to 1176 hours and to infinity
Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose
Cmax
Maximal concentration of drug in blood after single injection
Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Tmax
Time from 9 hours to time of maximal concentration of drug in blood after single injection
Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
T1/2
Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible
Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Kel
Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible
Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Clearance of BCD-131
Clearance of BCD-131 in blood after single injection
Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
AUEC (0-1176 Hours) - Reticulocytes
Area under effect curve (AUEC) "absolute reticulocyte count - time" from 0 to 1176 hours post-dose after single injection of study drug
Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
AUEC (0-1176 Hours) - Hemoglobin
Area under effect curve (AUEC) "hemoglobin - time" from 0 to 1176 hours post-dose after single injection of study drug
Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
AC-Emax - Reticulocytes
Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug
Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
AC-Emax - Hemoglobin
Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug
Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale
visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome
Time frame: intraoperative
Number of Participants With Adverse Events and Serious Adverse Events
Total incidence of adverse events (AE)/ serious adverse events (SAE)
Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Number of Participants With Local Reactions
Incidence of administration site reactions
Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Number of Participants With AE/SAE 3-4 Grade CTCAE
Incidence of Grade 3-4 AEs and SAEs.
Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Number of Participants With Early Withdrawal Due to AE
Frequency of early withdrawals due to AEs and SAEs
Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Number of Participants With Binding Antibodies to BCD-131
Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131
Time frame: 0, day 50 post-dose
| Milestone | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Area under curve (AUC) "concentration - time" from 0 hours to 1176 hours and to infinity
| pg*hr/ml | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC (0-1176 Hours) | 206974.500 (144988.500 to 485443.500) | 657417.000 (598401.500 to 666088.500) | 827904.750 (362302.000 to 1179816.500) | 1360020.000 (424094.000 to 1427990.750) | 1314197.750 (64430.000 to 1465335.500) | 3202606.500 (2173496.250 to 4300376.000) | 5220198.750 (4658082.250 to 5328878.250) | 688124.000 (478496.000 to 1252376.250) | 94628.375 (49807.250 to 113412.500) | 6382389.188 (4818041.5 to 6826251.75) | 2089193.125 (789943 to 2926898) |
Maximal concentration of drug in blood after single injection
| picogram per ml | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax | 585.000 (503.000 to 744.000) | 1035.000 (854.000 to 1761.000) | 2248.000 (1457.000 to 2566.000) | 3634.000 (2924.000 to 4954.000) | 3541.000 (150.000 to 4110.000) | 12023.000 (6863.000 to 12243.000) | 15433.000 (13286.000 to 16404.000) | 2298.000 (1849.000 to 6867.000) | 964.500 (870.000 to 1229.000) | 87526.5 (69859 to 93090) | 10588 (3713 to 11692) |
Time from 9 hours to time of maximal concentration of drug in blood after single injection
| hours | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax | 216.000 (96.000 to 504.000) | 168.000 (72.000 to 504.000) | 96.000 (8.000 to 96.000) | 72.000 (48.000 to 72.000) | 72.000 (48.000 to 168.000) | 120.000 (96.000 to 168.000) | 96.000 (72.000 to 96.000) | 48.000 (48.000 to 72.000) | 36.000 (8.000 to 36.000) | 0.75 (0.5 to 1) | 84 (72 to 96) |
Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible
| hours | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T1/2 | 322.094 (322.094 to 322.094) | — | 377.272 (281.082 to 473.461) | 212.231 (212.231 to 212.231) | 416.482 (326.648 to 506.316) | 191.477 (145.071 to 495.813) | 181.310 (168.649 to 186.681) | 114.855 (105.888 to 256.031) | 79.473 (44.619 to 104.605) | 116.125 (70.7 to 120.38) | 182.392 (123.71 to 197.76) |
Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible
| fraction per hour | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kel | 0.002152 (0.002152 to 0.002152) | — | 0.001965 (0.001464 to 0.002466) | 0.003266 (0.003266 to 0.003266) | 0.001746 (0.001369 to 0.002122) | 0.003620 (0.001398 to 0.004778) | 0.003823 (0.003713 to 0.004110) | 0.006057 (0.003734 to 0.006549) | 0.009019 (0.006697 to 0.019655) | 0.005977 (0.003424 to 0.006196) | 0.003828 (0.001367 to 0.00415) |
Clearance of BCD-131 in blood after single injection
| ml per hour | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clearance of BCD-131 | 17.393 (8.446 to 24.140) | 16.200 (15.313 to 21.808) | 33.337 (24.411 to 83.908) | 54.043 (48.530 to 225.304) | 92.812 (91.843 to 1820.580) | 65.259 (46.682 to 88.567) | 51.774 (51.147 to 57.320) | 108.993 (59.886 to 156.741) | 332.263 (304.017 to 602.322) | 29.84 (24.293 to 30.734) | 136.391 (48.481 to 202.399) |
Area under effect curve (AUEC) "absolute reticulocyte count - time" from 0 to 1176 hours post-dose after single injection of study drug
| cells (10^9) * hr/l | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUEC (0-1176 Hours) - Reticulocytes | 10568.04 (10107.60 to 10940.76) | 348.000 (144.000 to 1980.000) | 2868.000 (2664.000 to 17556.00) | 11004.00 (6006.000 to 13416.00) | 14481.60 (10366.80 to 15530.40) | 25512.00 (16476.00 to 30355.20) | 69120.00 (46183.20 to 81511.20) | 10269.72 (3121.200 to 16310.88) | 14223.60 (8736.000 to 21257.28) | 21370.44 (18081.6 to 22724.88) | 13129.2 (4432.56 to 15072) |
Area under effect curve (AUEC) "hemoglobin - time" from 0 to 1176 hours post-dose after single injection of study drug
| gr*hr/l | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUEC (0-1176 Hours) - Hemoglobin | 864.00 (528.00 to 2460.00) | 216.00 (0.00 to 1260.00) | 1992.00 (1152.00 to 3864.00) | 4752.00 (2688.00 to 6924.00) | 1548.00 (1320.00 to 10128.00) | 1392.00 (660.00 to 23460.00) | 3516.00 (2904.00 to 4248.00) | 3492.00 (720.00 to 6156.00) | 3120.00 (2112.00 to 4320.00) | 4008 (2340 to 4044) | 4632 (2448 to 4812) |
Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug
| 10e9 reticulocytes per liter" | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AC-Emax - Reticulocytes | 23.65 (17.15 to 31.34) | 6.00 (6.00 to 22.00) | 13.00 (11.00 to 34.00) | 27.00 (12.00 to 28.00) | 20.68 (17.00 to 26.00) | 112.00 (81.00 to 132.00) | 110.00 (69.00 to 171.00) | 58.00 (48.00 to 91.42) | 62.22 (48.00 to 153.10) | 70.18 (67 to 72.76) | 57.5 (45.4 to 58) |
Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug
| gramm per liter | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AC-Emax - Hemoglobin | 8.00 (3.00 to 11.00) | 2.00 (0.00 to 22.00) | 7.00 (5.00 to 9.00) | 9.00 (8.00 to 15.00) | 9.00 (6.00 to 21.00) | 6.00 (4.00 to 26.00) | 10.00 (8.00 to 10.00) | 10.50 (3.00 to 12.00) | 9.00 (8.00 to 13.00) | 11.00 (8.00 to 13.00) | 10.5 (9.00 to 12.00) |
visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome
| score on a scale | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale | 0 (0 to 2) | 0 (0 to 0) | 0 (0 to 2) | 2 (0 to 2) | 2 (0 to 2) | 0 (0 to 2) | 2 (0 to 2) | 0 (0 to 0) | 2 (0 to 2) | — | — |
Total incidence of adverse events (AE)/ serious adverse events (SAE)
| Participants | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events and Serious Adverse Events | 0 | 1 | 2 | 2 | 0 | 0 | 2 | 4 | 4 | 4 | 5 |
Incidence of administration site reactions
| Participants | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Local Reactions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Incidence of Grade 3-4 AEs and SAEs.
| Participants | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With AE/SAE 3-4 Grade CTCAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Frequency of early withdrawals due to AEs and SAEs
| Participants | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Early Withdrawal Due to AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131
| Participants | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Binding Antibodies to BCD-131 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over from the first administration of the first dose of the drug up to the end of follow up period (28 days after the last administration of the drug). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BCD-131, 0.05 mcg/kg Subcutaneously | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| BCD-131, 0.15 mcg/kg Subcutaneously | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| BCD-131, 0.40 mcg/kg Subcutaneously | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| BCD-131, 1.05 mcg/kg Subcutaneously | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| BCD-131, 1.70 mcg/kg SC | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| BCD-131, 2.25 mcg/kg SC | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| BCD-131, 4.45 mcg/kg Subcutaneously | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Mircera®, 1.20 mcg/kg Subcutaneously | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Aranesp®, 0.45 mcg/kg Subcutaneously | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| BCD-131, Optimal Dose, Intravenously | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| BCD-131, Optimal Dose, Subcutaneously | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Platelet count increasedBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 1/6 | 0/6 |
| eosinophils increasedBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 4/6 | 0/6 | 0/6 | 0/6 |
| Neutrophiles decreasedBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 1/6 | 3/6 |
| platelet count decreasedBlood and lymphatic system disorders | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 |
| monocytes count decreasedBlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 |
| basophils increasedBlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 2/6 | 0/6 | 0/6 |
| Blood bilirubin increasedHepatobiliary disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/6 | 2/6 | 2/6 | 0/6 |
| AST increasedBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/6 | 0/6 | 0/6 | 0/6 |
| Leucocytes decreasedBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 1/6 |
| HypoglycemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 1/6 |
| Age, Continuous(years) | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 24 (21 to 25) | 26 (22 to 36) | 30 (23 to 40) | 32 (23 to 36) | 26 (26 to 27) | 25 (22 to 32) | 25 (22 to 26) | 28 (22 to 31) | 28 (25 to 31) | 24 (23 to 29) | 25 (25 to 27) | 26 (23 to 30) |
| Sex: Female, Male(Participants) | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 45 |
| Race (NIH/OMB)(Participants) | BCD-131, 0.05 mcg/kg Subcutaneously | BCD-131, 0.15 mcg/kg Subcutaneously | BCD-131, 0.40 mcg/kg Subcutaneously | BCD-131, 1.05 mcg/kg Subcutaneously | BCD-131, 1.70 mcg/kg SC | BCD-131, 2.25 mcg/kg SC | BCD-131, 4.45 mcg/kg Subcutaneously | Mircera®, 1.20 mcg/kg Subcutaneously | Aranesp®, 0.45 mcg/kg Subcutaneously | BCD-131, Optimal Dose, Intravenously | BCD-131, Optimal Dose, Subcutaneously | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 45 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2016 to primary completion in Mar 2017, 9 months.
Results were first posted in Jul 2019, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.